CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Long-term efficacy and safety of elafibranor in primary biliary cholangitis: Interim results from the open-label extension of the ELATIVE trial up to 3 years
DOI 10.1055/s-0045-1810778
Bibliografische Angaben
Nachweis in CareLit
Autor:innenK V Kowdley, C L Bowlus, C Levy, U Akarca, M R Alvares-da-Silva, P Andreone, M Arrese, C Corpechot, H Elbeshbeshy, S Francque, M A Heneghan, P Invernizzi, I M Jacobson, D Jones, F C Kruger, E Lawitz, M J Mayo, M L Shiffman, M Sonderup, M G Swain, J M Valera, V Vargas, J M Vierling, A Villamil, C Ra…
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2025
Jahrgang / SeitenJg. 63 · S. e456-e457
Kernaussage aus der Literatur
Abstract-Vorschau
Long-term efficacy and safety of elafibranor in primary biliary cholangitis: Interim results from the open-label extension of the ELATIVE trial up to 3 years
Zitieren
Zitierempfehlung
K V Kowdley, C L Bowlus, C Levy, U Akarca, M R Alvares-da-Silva, P Andreone, M Arrese, C Corpechot, H Elbeshbeshy, S Francque, M A Heneghan, P Invernizzi, I M Jacobson, D Jones, F C Kruger, E Lawitz, M J Mayo, M L Shiffman, M Sonderup, M G Swain, J M Valera,… (2025) Long-term efficacy and safety of elafibranor in primary biliary cholangitis: Interim results from the open-label extension of the ELATIVE trial up to 3 years. Zeitschrift für Gastroenterologie, 63 (08), e456-e457. https://doi.org/10.1055/s-0045-1810778
Mit CareLit weiterarbeiten